Duramed's Cenestin (synthetic conjugated estrogens, A) direct-to-consumer print ad campaign emphasizes the plant-source of the product as an alternative to Wyeth-Ayerst's equine-derived Premarin.

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials